Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Shionogi will have exclusive worldwide rights to develop, manufacture, and commercialize the compounds generated from the collaboration
October 11, 2019
By: Kristin Brooks
Managing Editor, Contract Pharma
Shionogi & Co., Ltd. has entered into a new license agreement with Hsiri Therapeutics, Inc. for a collaborative research and development program to discover and develop additional novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB). This new collaboration will include technology that complements Shionogi’s earlier collaboration arrangement with Hsiri. The new technology licensed from Hsiri has a novel mechanism of action that will be complementary to Shionogi’s current research with Hsiri, and is anticipated to be more effective than current therapies for mycobacterial infections. Shionogi’s strength in small molecule drug discovery and development in the antibacterial area will support development of Hsiri’s innovative therapeutics in this collaboration. Under the terms of this agreement, Shionogi will have exclusive worldwide rights to develop, manufacture, and commercialize the compounds generated from the collaboration. Hsiri will receive an upfront license fee, potential development milestones, and royalty payments based on sales from Shionogi. It is reported that the number of patients suffering from NTM diseases has been increasing, especially in developed countries, in recent years. There is a medical need to develop novel anti-NTM drugs because of the long duration of treatment and insufficient treatment outcome of current therapeutics. TB is one of the three major infectious diseases in the world1, and new cases of TB are estimated to be 10.4 million/year.2 Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) have become a major public health concern, and novel drugs for MDR-TB and XDR-TB are anticipated. Shionogi’s research and development targets infectious disease as one of its priority areas. Through this cooperation, Shionogi aims to bring to market innovative drugs for the treatment of infectious diseases.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !